Prognostic Study of Inflammatory Markers in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Oct 7

PMID 39372707

Authors

Linbo Tang

Xinjing Li

Yongbin Wang

Yuanhe Tong

Affiliations

Soon will be listed here.

Abstract

Purpose: Inflammatory markers in the blood have been linked to tumor prognosis, but their specific prognostic significance in nasopharyngeal carcinoma (NPC) patients undergoing intensity-modulated radiotherapy (IMRT) is not well established. This study aims to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in this patient population.

Patients And Methods: A total of 406 non-metastatic NPC patients were included in the study. NLR, PLR, and LMR were stratified according to their average values. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Cox multivariate regression analysis was performed to evaluate the associations of NLR, PLR, and LMR with PFS and OS.

Results: Patients with NLR > 2.78 had worse PFS (P = 0.008) and OS (P < 0.001); PLR > 162.48 was related to lower PFS (P = 0.018) but not OS (P = 0.29); LMR > 5.05 showed no significant difference in PFS and OS compared to LMR ≤ 5.05 (P values were 0.13 and 0.94, respectively). Multivariate analysis indicated that NLR was an independent prognostic factor for PFS (HR, 1.674; 95% CI, 1.006-2.784; P = 0.047) and OS (HR, 4.143; 95% CI, 2.111-8.129; P = 0.000), while PLR and LMR did not demonstrate significant associations with PFS and OS.

Conclusion: This study identifies NLR as a novel and independent prognostic indicator for NPC patients receiving IMRT, offering valuable insights that could inform future clinical decision-making. In contrast, PLR and LMR did not demonstrate significant prognostic value in this context.

Citing Articles

Analysis of Prognostic Factors for Internal Carotid Artery Invasion by Nasopharyngeal Carcinoma.

Lien C, Yeh S, Cheng C, Chiang F, Hwang T, Cai B Cancers (Basel). 2025; 17(3).

PMID: 39941853 PMC: 11816255. DOI: 10.3390/cancers17030488.

References

Jiang Y, Huang S, Pan X, Ma J, Zhu X . The prognostic nutritional index represents a novel inflammation-nutrition-based prognostic factor for nasopharyngeal carcinoma. Front Nutr. 2023; 10:1036572. PMC: 9977787. DOI: 10.3389/fnut.2023.1036572. View

Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Ohsawa M . Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma. Onco Targets Ther. 2023; 16:263-273. PMC: 10103711. DOI: 10.2147/OTT.S404926. View

Guven D, Stephen B, Sahin T, Cakir I, Aksoy S . Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. Laryngoscope. 2023; 134(1):7-17. DOI: 10.1002/lary.30754. View

Arneth B . Tumor Microenvironment. Medicina (Kaunas). 2020; 56(1). PMC: 7023392. DOI: 10.3390/medicina56010015. View

Propper D, Balkwill F . Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19(4):237-253. DOI: 10.1038/s41571-021-00588-9. View

Feng Y, Zhang N, Wang S, Zou W, He Y, Ma J . Systemic Inflammation Response Index Is a Predictor of Poor Survival in Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Study. Front Oncol. 2020; 10:575417. PMC: 7759154. DOI: 10.3389/fonc.2020.575417. View

Kumar A, Gurram L, Naga Ch P, Nayak P, Mulye G, Chopra S . Correlation of Hematological Parameters With Clinical Outcomes in Cervical Cancer Patients Treated With Radical Radio(chemo)therapy: A Retrospective Study. Int J Radiat Oncol Biol Phys. 2023; 118(1):182-191. DOI: 10.1016/j.ijrobp.2023.07.022. View

Xu F, Ni W, Hua X, Xu C, Chen J, Cao W . A single center retrospective study assessing the prognostic significance of pre-treatment neutrophil/lymphocyte ratio in locally advanced nasopharyngeal carcinoma. Transl Cancer Res. 2023; 12(7):1672-1683. PMC: 10425666. DOI: 10.21037/tcr-23-528. View

Wang X, Yang M, Ge Y, Tang M, Rao B, Chen Y . Association of Systemic Inflammation and Malnutrition With Survival in Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy: Results From a Multicenter Cohort Study. Front Oncol. 2021; 11:766398. PMC: 8576523. DOI: 10.3389/fonc.2021.766398. View

10.

Liao L, Hsu W, Wang C, Lo W, Cheng P, Shueng P . Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients. Clin Otolaryngol. 2017; 43(2):463-469. DOI: 10.1111/coa.12992. View

11.

Ou D, Wang X, Wu M, Xue F, Li Y, Hu C . Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma. Strahlenther Onkol. 2019; 196(3):252-261. DOI: 10.1007/s00066-019-01529-3. View

12.

Chen Y, Sun J, Hu D, Zhang J, Xu Y, Feng H . Predictive Value of Pretreatment Lymphocyte-to-Monocyte Ratio and Platelet-to-Lymphocyte Ratio in the Survival of Nasopharyngeal Carcinoma Patients. Cancer Manag Res. 2021; 13:8767-8779. PMC: 8633848. DOI: 10.2147/CMAR.S338394. View

13.

Morimoto H, Tsujikawa T, Miyagawa-Hayashino A, Kimura A, Saburi S, Murakami N . Neutrophil-to-lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma. Head Neck. 2024; 46(8):1956-1964. DOI: 10.1002/hed.27671. View

14.

Bossi P, Chan A, Licitra L, Trama A, Orlandi E, Hui E . Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 32(4):452-465. DOI: 10.1016/j.annonc.2020.12.007. View

15.

Li J, Ye Y, Cai Y, Ji H, Qin W, Luo Y . Triglyceride-inflammation score established on account of random survival forest for predicting survival in patients with nasopharyngeal carcinoma: a retrospective study. Front Immunol. 2024; 15:1375931. PMC: 11082337. DOI: 10.3389/fimmu.2024.1375931. View

16.

Dennis M, Haddad R . Revisiting TNM staging for EBV-related nasopharyngeal carcinoma. Cancer Cell. 2024; 42(3):333-334. DOI: 10.1016/j.ccell.2024.01.014. View

17.

Ye M, Huang A, Yuan B, Tan G, Ai J, Liu H . Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2024; 281(4):1971-1989. DOI: 10.1007/s00405-024-08474-7. View

18.

Li Q, Yu L, Yang P, Hu Q . Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era. Cancer Manag Res. 2021; 13:6799-6810. PMC: 8418375. DOI: 10.2147/CMAR.S311094. View

19.

Peng R, Liang Z, Chen K, Li L, Qu S, Zhu X . Nomogram Based on Lactate Dehydrogenase-to-Albumin Ratio (LAR) and Platelet-to-Lymphocyte Ratio (PLR) for Predicting Survival in Nasopharyngeal Carcinoma. J Inflamm Res. 2021; 14:4019-4033. PMC: 8385134. DOI: 10.2147/JIR.S322475. View

20.

Peng Z, Wang Y, Fan R, Gao K, Xie S, Wang F . Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge. Cancers (Basel). 2022; 14(17). PMC: 9454547. DOI: 10.3390/cancers14174111. View